Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Cosmo Shares Advance After Dye Gets U.S. Patent

Cosmo Pharmaceuticals SpA gained the most in eight months after the Italian drugmaker said it got a patent in the U.S. for a dye to test for intestinal diseases.

Cosmo jumped as much as 11 percent to 67 Swiss francs in Zurich, the biggest intraday advance since Jan. 28, and was up 8.2 percent at 11:52 a.m. local time. The stock has doubled this year, giving the Lainate, Italy-based company a market value of 982 million francs ($1.1 billion). More than 25,000 shares were traded today, almost twice the daily average for the past three months.

The drugmaker will begin a final-phase clinical trial on the dye, called Methylene Blue MMX, in November after receiving the go-ahead from the European Medicines Agency for the study, Cosmo said today in a statement.

Canaccord Genuity Corp. raised its rating on Cosmo to buy from hold, with a price estimate of 73.40 francs a share.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.